William Waldegrave - GW Pharmaceuticals Non-Executive Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;padding-top: 25px;;'>GP</div>
GWPH -- USA Stock  

USD 127.90  0.21  0.16%

The Rt. Hon. Lord William Arthur Waldegrave is NonExecutive Independent Director of the Company. He served as a Conservative Member of the British Parliament from 1979 to 1997 including sixteen years as a Government Minister, of which seven years were as a Cabinet Minister . Educated at Oxford University and Harvard, before entering Parliament he worked in the Cabinet Office in Whitehall as Political Secretary to Prime Minister Edward Heath and for GEC Ltd. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University and a Distinguished Fellow of All Souls College, Oxford and an Honorary Fellow of Corporationrations Christi College, Oxford. From 19982008 he worked at Deutsche Kleinwort Benson and UBS. From 19982015, he served as Chairman of Biotechnology Growth Trust plc. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation, and a former Chairman of the National Museum of Science and Industry.
  Director Since 2017      
(44) 1223 235667  www.gwpharm.com

William Waldegrave Latest Insider Activity

GW Pharmaceuticals Management Efficiency

GW Pharmaceuticals Plc has return on total asset (ROA) of (5.79) % which means that it has lost $5.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.88 %, meaning that it created $4.88 on every $100 dollars invested by stockholders. GW Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to decrease to -17.2. The current Return on Average Assets is estimated to decrease to -0.01GW Pharmaceuticals Revenue to Assets are most likely to slightly decrease in the upcoming years. The last year's value of Revenue to Assets was reported at 0.0101. The current Total Assets Per Share is estimated to increase to 2.01, while Total Assets are estimated to decrease to roughly 884.4 M. The current Tax Liabilities is estimated to increase to about 619.8 K, while Total Liabilities is estimated to decrease to roughly 151.2 M.
The company currently holds 40.28 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 6.37, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives


Frans HoutenNovartis AG
Franklyn PrendergastEli Lilly And
Carlos RepresasMerck Company
Michael GrobsteinBristol Myers Squibb
Roy AndersonGlaxoSmithKline PLC
Stacey CartwrightGlaxoSmithKline PLC
Marla SalmonGrifols S A
JeanPhilippe CourtoisAstrazeneca PLC
David HooverEli Lilly And
Simon DingemansGlaxoSmithKline PLC
Luis BobadillaGrifols S A
Ronald WilliamsJohnson Johnson
Pierre LandoltNovartis AG
Robert BertoliniBristol Myers Squibb
Mary CoeMerck Company
Jennifer DoudnaJohnson Johnson
Peter WendellMerck Company
Katherine BaickerEli Lilly And
Jackson TaiEli Lilly And
Mary BeckerleJohnson Johnson
Cornelia BargmannAstrazeneca PLC

Company Summary

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. GW Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 901 people.GW Pharmaceuticals Plc (GWPH) is traded on BATS Exchange in USA. It is located in Sovereign House Vision Park, Chivers Way Histon, Cambridge CB24 9BZ, United Kingdom and employs 901 people. GW Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

GW Pharmaceuticals Plc Leadership Team

William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

Stock Performance Indicators

Did you try this?

Run Idea Analyzer Now


Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page